Research programme: designed repeat proteins - Molecular Partners/Janssen

Drug Profile

Research programme: designed repeat proteins - Molecular Partners/Janssen

Alternative Names: MP 0210; MP 0270

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator Molecular Partners AG
  • Developer Janssen Biotech; Molecular Partners AG
  • Class Proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Immunological disorders; Inflammation

Most Recent Events

  • 06 Oct 2016 Janssen terminates its license and collaboration agreement, to develop multi-DARPin® drug candidates, with Molecular Partners AG
  • 13 Oct 2015 Preclinical development is ongoing for the treatment of inflammatory and autoimmune diseases, including rheumatoid arthritis and asthma
  • 09 Dec 2011 Molecular Partners and Janssen Biotech have expanded their exsiting agreement for the development of multispecific DARPin-based products in immunological disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top